Efficacy of Amikacin Combinations for Nocardiosis

  • Kanemitsu Keiji
    Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
  • Kunishima Hiroyuki
    Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
  • Saga Tomoo
    Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
  • Harigae Hideo
    Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
  • Ishikawa Shiho
    Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
  • Takemura Hiromu
    Department of Microbiology, St. Marianna University School of Medicine
  • Kaku Mitsuo
    Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine

この論文をさがす

抄録

We isolated five bacterial strains from patients diagnosed as having nocardiosis. Bacterial species were identified based on the similarities in the nucleotide sequences of 16S ribosomal RNAs. Three of the five strains were identified as Nocardia asteroids, but unexpectedly other two were Streptomyces hygroscopicus and Rothia dentocariosa. The latter two species are not members of the family Nocardiaceae. We investigated the susceptibilities of these five strains to the following nine antimicrobial agents: trimethoprim/sulfamethoxazole (TMP/SMX), minocycline (MINO), erythromycin (EM), amikacin (AMK), cefotaxime (CTX), faropenem (FRPM), imipenem (IPM), ciprofloxacin (CPFX), and sparfloxacin (SPFX). The minimum inhibitory concentration (MIC) ranges (mg/ml) were as follows: TMP-SMX, 4->32; MINO, 0.125-8; EM, ≤0.016->32; AMK, 1-2; CTX, 0.063->32; FRPM, 0.063-16; IPM, 0.125-2; CPFX, 4-32; and SPFX, 0.5-16. Moreover, the synergistic effects of AMK in combination with each of TMP-SMX, MINO, EM, CTX, IPM, and SPFX were investigated by checkerboard synergy testing. No antagonism was recognized for the three N. asteroides strains. Synergistic and additive effects were observed for the combinations of AMK with CTX, IPM, or SPFX.

収録刊行物

参考文献 (45)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ